^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Clear Cell Renal Cell Carcinoma |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Pegasys (pegylated interferon α -2a) (IFNα stimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
The NCCN Kidney Cancer panel recommends bevacizumab in combination with IFN-α as a category 1 option, useful under certain circumstances, for first-line treatment of patients of all risk groups with relapsed or medically unresectable clear cell stage IV RCC.
